Literature DB >> 11280773

p27Kip1 is required for PTEN-induced G1 growth arrest.

A R Gottschalk1, D Basila, M Wong, N M Dean, C H Brandts, D Stokoe, D A Haas-Kogan.   

Abstract

The tumor suppressor PTEN is one of the most commonly inactivated genes in human cancer. Glioblastoma multiforme cells harboring mutant PTEN have abnormally high levels of 3' phosphoinositides and elevated protein kinase B activity. Expression of wild-type PTEN in glioma cells, containing endogenous mutant PTEN, reduces 3' phosphoinositides levels, inhibits PKB activity, and induces G1 cell cycle arrest. We investigated the mechanism of the PTEN-induced growth arrest in glioma cell lines. Expression of PTEN is associated with increased expression of p27Kip1, decreased expression of cyclins A and D3, inhibition of cdk2 activity, and dephosphorylation of pRb. Inactivation of p53, by the human papilloma virus E6 oncoprotein, does not prevent PTEN-induced G1 arrest, implying that p53 is not required for G1 arrest. In contrast, p27Kip1 antisense oligonucleotides abrogated the growth arrest induced by PTEN. Furthermore, blocking p27Kip1 expression prevented the PTEN-induced reduction of cyclin-dependent kinase 2 activity, indicating that p27Kip1 functions upstream of cyclin-dependent kinase 2 in the PTEN regulatory cascade. These results implicate p27Kip1 as a critical mediator of PTEN-induced G1 arrest.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11280773

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Suppression of gastric cancer growth by adenovirus-mediated transfer of the PTEN gene.

Authors:  Ying Hang; Yong-Chen Zheng; Yan Cao; Qing-Shan Li; Yu-Jie Sui
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

2.  Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi.

Authors:  Benoit Bilanges; David Stokoe
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

3.  MicroRNA in Melanoma.

Authors:  Paul M Howell; Xiaobo Li; Adam I Riker; Yaguang Xi
Journal:  Ochsner J       Date:  2010

Review 4.  Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding.

Authors:  Arshawn Sami; Michael Karsy
Journal:  Tumour Biol       Date:  2013-04-30

5.  PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.

Authors:  Jean L Nakamura; Amelia Karlsson; Nils D Arvold; Alexander R Gottschalk; Russell O Pieper; David Stokoe; Daphne A Haas-Kogan
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

6.  PTEN represses RNA Polymerase I transcription by disrupting the SL1 complex.

Authors:  Cheng Zhang; Lucio Comai; Deborah L Johnson
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

7.  Relation of overexpression of S phase kinase-associated protein 2 with reduced expression of p27 and PTEN in human gastric carcinoma.

Authors:  Xiu-Mei Ma; Ying Liu; Jian-Wen Guo; Jiang-Hui Liu; Lian-Fu Zuo
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

Review 8.  Cell Cycle Control by PTEN.

Authors:  Andrew Brandmaier; Sheng-Qi Hou; Wen H Shen
Journal:  J Mol Biol       Date:  2017-06-09       Impact factor: 5.469

9.  Antigen-induced Pten gene deletion in T cells exacerbates neuropathology in experimental autoimmune encephalomyelitis.

Authors:  Trina A Johnson; Shigeki Tsutsui; Frank R Jirik
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

10.  Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.

Authors:  Salvatore Lopez; Carlton L Schwab; Emiliano Cocco; Stefania Bellone; Elena Bonazzoli; Diana P English; Peter E Schwartz; Thomas Rutherford; Roberto Angioli; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2014-08-27       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.